Kate Rochlin
President & Chief Operating Officer IN8Bio
Seminars
Thursday 16th October 2025
Panel Discussion: Investigating Preclinical Platforms for Autoimmune T-Cell Engagers From Human Relevant Assays to Regulatory Confidence
2:40 pm
- For TCEs in autoimmunity, conventional preclinical tools, often adapted from oncology, fall short in capturing the inflammatory, chronic, and tissue-specific nature of disease.
- This panel will explore how to build assays that reflect real autoimmune biology, capture safety-relevant signals, and avoid reliance on transgenic animals. With human target expression and immune context being essential, developers are rethinking how they model tissue penetration, subset-specific depletion, and chronic inflammatory responses e.g. for emerging modalities like gamma delta T-Cell engagers.
- Regulatory expectations are also evolving, and this session will address what evidence best supports safe and effective IND filings.
- Building disease-relevant in vitro systems that incorporate inflammatory cytokine environments to reflect autoimmune activation states
- Demonstrating selective target cell depletion and tissue or lymph node engagement in the absence of exaggerated cytokine release or off-target killing
- Replicating chronic, low-grade inflammatory contexts in preclinical assays to detect tolerability and null responses rather than acute cytotoxic triggers
- Evaluating the translational relevance of preclinical models, such as for gamma delta T-cell engagers and define how to justify safety and efficacy without conventional animal studies
Thursday 16th October 2025
Activating the Potential of Gamma Delta T-Cells in Preclinical Models: A Next-Generation Strategy to Minimize CRS & Rethink TCE Safety in Autoimmunity
1:00 pm
- How to selectively target powerful but rare cell-types such as gamma-delta T cells for target cell elimination, alternatives to CD3
- Solving the scarcity issue: How to unlock the power of gamma delta T-cell engagers through novel design or mechanism to expand and activate gamma-delta T cells.
- Discussion of the shifting paradigm as we move from Oncology to Autoimmune indications in T cell engagers, can we realize the potential of safe and deep immune reset
